Additive effects of estrogen replacement therapy and bisphosphonates on osseointegration of hydroxyapatite-coated titanium screws in ovariectomized rats.
OBJECTIVE
This study investigated the effect of locally immobilized bisphosphonates and systemic estrogen replacement therapy on fixation of hydroxyapatite-coated screws in ovariectomized rats.


METHODS
Twelve weeks after being ovariectomized, each of the 20 rats received 2 hydroxyapatite-coated screws in the proximal tibia, with or without immobilized bisphosphonates. Half of the animals also received subcutaneous injections of 17beta-estradiol. Thus, there were 4 groups: control, estrogen, bisphosphonates, and estrogen plus bisphosphonates. Tibiae with screws were measured by microscopic computerized tomography and push-out test 12 weeks after implantation.


RESULTS
Combined treatment had the strongest effects, with the bone volume ratio around screws and the percentage of osteointegration significantly increased by 2.3-fold and 1.9-fold and the push-out force by 3.3-fold compared with untreated control samples. Monotherapy also enhanced the fixation of screws, although less.


CONCLUSIONS
Systemic estrogen replacement therapy and locally immobilized bisphosphonates had additive effects on fixation of hydroxyapatite-coated screws in ovariectomized rats.
Li
Yunfeng
Y
State Key Laboratory of Oral Diseases, Sichuan University, Chengdu, Sichuan, China.
Gao
Ying
Y
Song
Guodong
G
Liu
Xianwen
X
Hu
Jing
J
D000497:Alloys; D000818:Animals; D001696:Biomechanical Phenomena; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001863:Bone Screws; D020099:Coated Materials, Biocompatible / Q000737:chemistry*; D003722:Dental Alloys / Q000737:chemistry*; D004164:Diphosphonates / Q000008:administration & dosage / Q000627:therapeutic use*; D017886:Durapatite / Q000737:chemistry*; D004958:Estradiol / Q000008:administration & dosage; D015914:Estrogen Replacement Therapy; D004967:Estrogens / Q000008:administration & dosage; D005260:Female; D007093:Imidazoles / Q000627:therapeutic use; D007279:Injections, Subcutaneous; D016348:Osseointegration / Q000187:drug effects*; D010052:Ovariectomy; D051381:Rats; D017207:Rats, Sprague-Dawley; D033081:Shear Strength; D013314:Stress, Mechanical; D013977:Tibia / Q000601:surgery; D013997:Time Factors; D014025:Titanium / Q000737:chemistry*; D055114:X-Ray Microtomography; D000077211:Zoledronic Acid
D000497:Alloys; D050071:Bone Density Conservation Agents; D020099:Coated Materials, Biocompatible; D003722:Dental Alloys; D004164:Diphosphonates; D004967:Estrogens; D007093:Imidazoles; C031462:titanium alloy (TiAl6V4); D004958:Estradiol; D000077211:Zoledronic Acid; D017886:Durapatite; D014025:Titanium